Everolimus affects vasculogenic mimicry in renal carcinoma resistant to sunitinib.
|
| Abstract |
Angiogenesis is hallmark of clear cell renal cell carcinogenesis. Anti-angiogenic therapies have been successful in improving disease outcome; however, most patients treated with anti-angiogenic agents will eventually progress. In this study we report that clear cell renal cell carcinoma was associated with vasculogenic mimicry in both mice and human with tumor cells expressing endothelial markers in the vicinity of tumor vessels. We show that vasculogenic mimicry was efficiently targeted by sunitinib but eventually associated with tumor resistance and a more aggressive phenotype both in vitro and in vivo. Re-challenging these resistant tumors in mice, we showed that second-line treatment with everolimus particularly affected vasculogenic mimicry and tumor cell differentiation compared to sorafenib and axitinib. Finally, our results highlighted the phenotypic and genotypic changes at the tumor cell and microenvironment levels during sunitinib response and progression and the subsequent improvement second-line therapies bring to the current renal cell carcinoma treatment paradigm.
|
|---|---|
| Authors | Maria Serova, Annemilaï Tijeras-Raballand, Celia Dos Santos, Matthieu Martinet, Cindy Neuzillet, Alfred Lopez, Dianne C Mitchell, Brad A Bryan, Guillaume Gapihan, Anne Janin, Guilhem Bousquet, Maria Eugenia Riveiro, Ivan Bieche, Sandrine Faivre, Eric Raymond, Armand de Gramont |
| Journal | Oncotarget (Oncotarget) Vol. 7 Issue 25 Pg. 38467-86 (Jun 21 2016) ISSN: 1949-2553 [Electronic] United States |
| PMID | 27509260 (Publication Type: Journal Article) |
| Chemical References |
|
| Topics |
|
Join CureHunter, for free Research Interface BASIC access!
Realize the full power of the drug-disease research graph!